Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to ten Expanded partnership highlights the parties’ emerging